Goals

  • Improve diagnostic, predictive and monitoring modalities and prevent disease progression.
  • Develop novel targeted forms of treatment, both immunological (antibody/DC vaccines/CART/NK) and chemical (PROTACS, small molecules) and perform investigator-initiated phase I/II trials.
  • Improve quality of life by reducing early and late treatment-related toxicity and avoiding disease progression.
  • Enhance patient engagement and shared decision making by personalized, eHealth-based care platforms.


go to main content
Research Research programs Treatment improvement for severe hematological diseases

Our purpose

We aim to unravel the pathophysiological basis of hematological disease, understand the biological consequences and define possibilities for therapeutic intervention.

Goals

See some of the most important goals for this research program.

read more

Research groups contributing to this research program

Experimental hematology

Joop Jansen's research group studies molecular mechanisms of leukemia development with a focus on epigenetic modifiers, splicing factors and transcription factors. In addition, factors influencing clonal evolution in premalignant and malignant states is studied.

Experimental immunology

Annemiek van Spriel's research group studies the immune system at the cellular and molecular level. 

Hematology

Nicole Blijlevens's research group wants to develop innovative and effective forms of supportive and integrated care to reduce toxicity and improve tolerability of therapy.

Spokesperson(s) for this research program

Spokesperson

dr. Bert van der Reijden

contact form